Real-World study shows ofatumumab cuts relapses in MS patients
NCT ID NCT06251986
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study looked at how well and how safely ofatumumab (Kesimpta®) works for people with relapsing multiple sclerosis in Spain. Researchers followed 310 patients who had been on the drug for at least a year. The main goal was to see if the number of relapses (flare-ups of symptoms) went down. This was an observational study, meaning no new treatments were given—just data collected from regular care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING FORMS OF MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706, Spain
-
Novartis Investigative Site
Palma, Balearic Islands, 07120, Spain
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Novartis Investigative Site
Albacete, Castille-La Mancha, 02006, Spain
-
Novartis Investigative Site
Salt, Girona, 17190, Spain
-
Novartis Investigative Site
Logroño, La Rioja, 26006, Spain
-
Novartis Investigative Site
Fuenlabrada, Madrid, 28942, Spain
-
Novartis Investigative Site
Majadahonda, Madrid, 28222, Spain
-
Novartis Investigative Site
Pamplona, Navarre, 31008, Spain
-
Novartis Investigative Site
Vigo, Pontevedra, 36212, Spain
-
Novartis Investigative Site
Santa Cruz, Santa Cruz de Tenerife, 38009, Spain
-
Novartis Investigative Site
Barakaldo, Vizcaya, 48903, Spain
-
Novartis Investigative Site
Alicante, 03010, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Burgos, 09006, Spain
-
Novartis Investigative Site
Cáceres, 10004, Spain
-
Novartis Investigative Site
Córdoba, 14004, Spain
-
Novartis Investigative Site
Granada, 18016, Spain
-
Novartis Investigative Site
León, 24080, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Madrid, 28046, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Seville, 41009, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Zaragoza, 50009, Spain
Conditions
Explore the condition pages connected to this study.